Medication Monitor

Generic Name (Trade Name—Company)
August 1, 2019


(No trade name—Legacy Pharmaceutical)
Four lots of losartan tablets contain trace amounts of NMBA

On July 15, Legacy Pharmaceutical expanded its consumer-level recall of three repackaged lots of losartan tablets 50 mg (NDC 68645-494-54) to include one additional lot. This recall was prompted by Torrent Pharmaceuticals's nationwide recall of losartan tablets, which were found to contain trace amounts of N-nitroso N-methyl 4-amino butyric acid (NMBA), a potential human carcinogen. 

The product is used to treat high blood pressure and congestive heart failure and is packaged in 30-count bottles.

The affected losartan includes four repackaged lots numbers (three initial repackaged lots and one expanded repackaged lot): 180190, 180191, 181597, and 181598.

To date, Legacy has not received any reports of adverse events related to this recall.